A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Richardson, Paul G.
Attal, Michel
Rajkumar, S. Vincent
San Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn Penkus
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth Carl
机构：
[1] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] IUCT Oncopole, Toulouse, France
[3] Mayo Clin, Rochester, MN USA
[4] Clin Univ Navarra, Navarra, Spain
[5] Ankara Univ, Ankara, Turkey
[6] Vseobecna Fak Nemocnice V Praze, Prague, Czech Republic
[7] CHRU Lille, Lille, France
[8] Oslo Univ Hosp, Oslo, Norway
[9] CHU Nantes, Hotel Dieu, Nantes, France
[10] Univ Athens, Athens, Greece
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Univ Hosp Olomouc, Olomouc, Czech Republic
[13] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy
[14] Epworth Healthcare, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[16] Sanofi R&D, Oncol, Vitry Sur Seine, France
[17] Sanofi, Cambridge, MA USA
[18] Sanofi US, Cambridge, MA USA
[19] Sanofi R&D, Vitry Sur Seine, France
[20] Sanofi, Vitry Sur Seine, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8004
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
    San Miguel, Jesus
    Weisel, Katja
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Oriol, Albert
    Alegre, Adrian
    Chen, Christine
    Cavo, Michele
    Garderet, Laurent
    Ivanova, Valentina
    Martinez-Lopez, Joaquin
    Belch, Andrew
    Palumbo, Antonio
    Schey, Stephen
    Sonneveld, Pieter
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
  • [32] POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
    Matous, J.
    Siegel, D.
    Lonial, S.
    Harvey, R. D.
    Kasserra, C.
    Li, Y.
    Chen, M.
    Doerr, T.
    Sternas, L.
    Zaki, M.
    Jacques, C.
    Shah, J.
    HAEMATOLOGICA, 2015, 100 : 507 - 508
  • [33] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
    Schey, Steve
    Dhanasiri, Sujith
    Lee, Dawn
    Sternas, Lars
    Yu, Xin
    Zaki, Mohamed H.
    Elvidge, Jamie
    O'Dwyer, Michael
    BLOOD, 2014, 124 (21)
  • [34] Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
    Nagda, Priti
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (02) : 119 - 119
  • [35] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [36] Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Zheng, Cheng
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S424
  • [37] Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
    Nagda, Priti
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 7 - 7
  • [38] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Weisel, Katja
    Bentur, Ohad
    Van Domelen, Dane
    Boccadoro, Mario
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
  • [39] Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
    Richardson, Paul G.
    Rocafiguera, Albert Oriol
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darell
    Facon, Thierry
    San-Miguel, Jesus
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Zaki, Mohamed H.
    Anderson, Kenneth Carl
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY
    Wester, R.
    Dinmohamed, A.
    Sonneveld, P.
    Broijl, A.
    Blijlevens, N.
    HAEMATOLOGICA, 2017, 102 : 533 - 534
12345